Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denifanstat in metabolic syndrome
NCT02948569Phase 2Completed
- Sponsor
- University of Missouri
- Start
- Feb 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denifanstat in metabolic syndrome, sponsored by University of Missouri. Primary endpoint: Change in Hepatic Lipogenesis at 10 days. Started Feb 2017; status: completed.
02
Drugs
denifanstat
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT02948569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948569.